$0.43
7.46%
Nasdaq, Nov 20, 03:59 pm EST. Closed.
ISIN
US2312692005
Symbol
CRIS

Curis, Inc. Stock price

$0.43
+0.03 6.86% 1M
-9.48 95.69% 6M
-19.32 97.84% YTD
-21.17 98.02% 1Y
-168.77 99.75% 3Y
-2,039.57 99.98% 5Y
-6,659.57 99.99% 10Y
-3,319.57 99.99% 20Y
Nasdaq, Closing price Fri, Nov 20 2026
-0.04 9.03%
ISIN
US2312692005
Symbol
CRIS
Industry

Is Curis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$4.1m
Enterprise Value
$-1.0m
Net debt
positive
Cash
$5.1m
Shares outstanding
2.0m
Valuation
P/E
negative
P/S | estimate
0.9 | -
EV/Sales | estimate
negative | -
EV/FCF | ex SBC
0.0 | 0.0
P/B
0.9
Financial Health
Equity Ratio
27.4%
Return on Equity
-138.8%
ROCE
-165.7%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$2.9m | 66.4%
SBC as % of FCF
-
SBC Growth 1Y
-42.3%
Share Count Growth 1Y
261.1%
Shareholder Yield
-
Financials
Revenue | estimate
$4.3m | $0.0
EBITDA
$-8.7m
EBIT
$-8.8m
Net Income
$-21.2m
Free Cash Flow | ex SBC
$-30.6m | $-33.5m
Growth
Revenue | estimate
-62.2% | -100.0%
EBITDA
77.0%
EBIT
76.9%
Net Income
45.7%
Free Cash Flow
-0.4%
Margin
Gross
99.7%
EBITDA
-201.2%
EBIT
-203.2%
Net
-490.3%
Free Cash Flow | ex SBC
-709.0% | -775.4%
More
EPS
$-9.9
FCF per Share
$-15.7
Short interest
15.5%
Employees
22
Rev per Employee
$430.0k

Curis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Curis, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Curis, Inc. forecast:

Buy
89%
Hold
11%

Curis, Inc. Events

Past Events
NOV
12
Q3 2026 Earnings Call
8 days ago
JUL
22
Special Call - Curis, Inc.
4 months ago
MAY
12
Q1 2026 Earnings Call
6 months ago
MAR
19
Q4 2025 Earnings Call
8 months ago
NOV
6
Q3 2025 Earnings Call
about one year ago

Financial data from Curis, Inc.

Jun '26
+/-
%
4.31 4.31
62% 62%
100%
- Direct Costs 0.02 0.02
71% 71%
0%
4.30 4.30
62% 62%
100%
- Selling and Administrative Expenses 15 15
1% 1%
344%
- Research and Development Expense 25 25
27% 27%
590%
-8.68 -8.68
77% 77%
-201%
- Depreciation and Amortization 0.08 0.08
56% 56%
2%
EBIT (Operating Income) EBIT -8.76 -8.76
77% 77%
-203%
Net Profit -21 -21
46% 46%
-491%

In millions USD.

Don't miss a Thing! We will send you all news about Curis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Curis, Inc. Stock News

Neutral
PRNewsWire
●
8 days ago
Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass.
Neutral
PRNewsWire
●
about one month ago
LEXINGTON, Mass., Oct. 16, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into securities purchase agreements with certain existing healthcare focused institutional investors for the purchase a...
More Curis, Inc. News

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Head office United States
CEO Mr. Dentzer
Employees 22
Founded 2000
Website www.curis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today